Skip to content

Can MRI accurately assess metastasis in the abdominal cavity from ovarian cancer?

Can diffusion-weighted MRI replace exploratory laparoscopy in the assessment of peritoneal carcinomatosis from ovarian cancer?

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12618001809224
Acronym
DW-MRI-OC
Enrollment
140
Registered
2018-11-06
Start date
2018-12-03
Completion date
2021-08-01
Last updated
2018-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This research study is designed to assess whether a special MRI scan can accurately predict the extent of cancer spread in the abdominal cavity in advanced ovarian cancer. Who is it for? You may be eligible for this study if you have a diagnosis of metastatic ovarian cancer and are aged over 18 years old. Study details All participants in this study will undergo an MRI scan no longer than 2 weeks prior to their routine diagnostic laparoscopy. This scan will take approximately 60 minutes. Participants will also give informed consent for access to their medical records. It is hoped this research might demonstrate that MRI scans can replace surgery when assessing the spread of advanced ovarian cancer in the abdominal cavity.

Interventions

All study patients will have a diffusion weighted MRI scan prior to surgery. This is a single MRI which will take approximately 1 hour to perform. It will be performed up to a week prior to surgery. Three T high field strength MR scanner will be used . High performance gradients (50 mT/m, 200 mT/m/sec) are advantageous for high quality DW imaging. The MRI scan will be performed by the MRI radiographer with the radiologist supervising. Intravenous gadolinium contrast will be administered usin

All study patients will have a diffusion weighted MRI scan prior to surgery. This is a single MRI which will take approximately 1 hour to perform. It will be performed up to a week prior to surgery. Three T high field strength MR scanner will be used . High performance gradients (50 mT/m, 200 mT/m/sec) are advantageous for high quality DW imaging. The MRI scan will be performed by the MRI radiographer with the radiologist supervising. Intravenous gadolinium contrast will be administered using a power injector at an injection rate of 2 cc per second. We will use a single dose 0.1 mmol/kg of MultiHance® (gadobenate dimeglumine) (Bracco).

Sponsors

Mater Adults Hospital
Lead SponsorHospital

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Diagnosis
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. diagnosis of metastatic ovarian cancer and who can 2. ability to give informed consent 3. happy to participate

Exclusion criteria

• Patients who have a heart pacemaker may not have an MRI scan • Patients who have a metallic foreign body (metal sliver) in their eye, or who have an aneurysm clip in their brain, cannot have an MRI scan since the magnetic field may dislodge the metal • Patients with severe claustrophobia may not be able to tolerate an MRI scan, although more open scanners are now available, and medical sedation is available to make the test easier to tolerate • Patients who have had metallic devices placed in their back (such as pedicle screws or anterior interbody cages) can have an MRI scan, but the resolution of the scan is often severely hampered by the metal device and the spine is not well imaged.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026